ACTH protects against glucocorticoid-induced osteonecrosis of bone.
We report that adrenocorticotropic hormone (ACTH) protects against osteonecrosis of the femoral head induced by depot methylprednisolone acetate (depomedrol). This therapeutic response likely arises from enhanced osteoblastic support and the stimulation of VEGF by ACTH; the latter is largely responsible for maintaining the fine vascular network that surrounds highly remodeling bone. We suggest examining the efficacy of ACTH in preventing human osteonecrosis, a devastating complication of glucocorticoid therapy.
Zaidi
Mone
M
The Mount Sinai Bone Program, Mount Sinai School of Medicine, New York, NY 10029, USA. mone.zaidi@mssm.edu
Sun
Li
L
Robinson
Lisa J
LJ
Tourkova
Irina L
IL
Liu
Li
L
Wang
Yujuan
Y
Zhu
Ling-Ling
LL
Liu
Xuan
X
Li
Jianhua
J
Peng
Yuanzhen
Y
Yang
Guozhe
G
Shi
Xingming
X
Levine
Alice
A
Iqbal
Jameel
J
Yaroslavskiy
Beatrice B
BB
Isales
Carlos
C
Blair
Harry C
HC
D016475:3T3 Cells; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D019610:Cytoprotection / Q000187:drug effects; D005260:Female; D005269:Femur / Q000187:drug effects / Q000473:pathology*; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D011817:Rabbits; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis
D005938:Glucocorticoids; D020011:Protective Agents; D042461:Vascular Endothelial Growth Factor A; D000324:Adrenocorticotropic Hormone